SLNO Soleno Therapeutics Inc.

+0.08  (+4%)
Previous Close 1.95
Open 1.92
Price To Book 2.74
Market Cap 64506466
Shares 31,776,584
Volume 82,818
Short Ratio
Av. Daily Volume 1,957,334

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due late-2019.
Diazoxide Choline Controlled-Release (DCCR) - DESTINY PWS
Prader-Willi syndrome (PWS)

Latest News

  1. Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results
  2. Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
  3. Small Drug Stocks Outlook: Near-Term Prospects Encouraging
  4. Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
  5. Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
  6. Will Capnia Continue to Surge Higher?
  7. Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice
  8. Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference
  9. Soleno Therapeutics Inc (SLNO) Files 10-K for the Fiscal Year Ended on December 31, 2018
  10. Soleno Therapeutics, Analyst Review and Pipeline Progress
  11. Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
  12. Four Healthcare Stocks Picking Up Speed On Friday
  13. Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today
  14. The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA
  15. Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
  16. Soleno Therapeutics to Participate in Two Upcoming Investor Conferences
  17. Soleno Therapeutics Announces $16.5 Million Private Placement
  18. Is Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) CEO Pay Justified?
  19. Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018
  20. Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results